| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2010: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2009: ¥12,610,000 (Direct Cost: ¥9,700,000、Indirect Cost: ¥2,910,000)
|
|---|
| Research Abstract |
In order to improve the prognosis of patients with head and neck cancer, We have conducted clinical studies with α-GalCer-pulsed antigen presenting cells (APCs) administered in the nasal submucosa of patients with advanced pharyngeal cancer after standard therapies or with malignant head and neck melanoma after heavy iron therapy as an adjuvant therapy and evaluated the safety and feasibility of such an adjuvant therapy. Although median follow-up period is only 2 years and it is difficult to say definitive conclusion, overall survival seems to be improved in immunotherapy group with α-GalCer-pulsed APCs. Further studies to certify the clinical benefits are required.
|
